Product approval information is indicated for the treatment of acute bleeding episodes in adults and adolescents with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. for use in adults and children with hemophilia B for: (1) On-demand treatment and control of bleeding episodes; (2) Perioperative management of bleeding.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/YxJEalG
No comments:
Post a Comment